올리고뉴클레오티드 CDMO 시장 : 서비스(수탁 제조(임상·상업)·개발), 유형(ASO·siRNA), 용도(치료·연구·진단), 최종 사용자(제약 및 바이오테크놀러지), 지역, 경쟁사별 예측(-2031년)

The oligonucleotide CDMO market is expected to reach USD 11.14 billion in 2031, up from USD 3.88 billion in 2026, at a CAGR of 23.5% over the forecast period. The oligonucleotide CDMO market is expanding as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing to support growing oligonucleotide pipelines. Growing CDMO partnerships to enable scalability are driving demand for process development, synthesis, purification, analytical testing, and GMP manufacturing as programs advance toward clinical and commercial stages. Sponsors are increasingly seeking CDMOs with flexible capacity and integrated capabilities to support development through commercial manufacturing.

However, the complexities of therapeutic oligonucleotide manufacturing remain a key restraint. Longer sequences, chemical modifications, and conjugation can increase synthesis and purification challenges. Maintaining consistent quality during scale-up also requires specialized equipment, validated processes, and skilled personnel. Consequently, CDMOs with scalable infrastructure and strong analytical capabilities are better positioned to support complex oligonucleotide programs.

"Antisense oligonucleotides segment is expected to grow at the highest CAGR during the forecast period"

The antisense oligonucleotide (ASO) segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of ASO-based therapeutics and increased outsourcing of manufacturing. ASO programs require specialized synthesis, purification, analytical testing, and GMP manufacturing capabilities. The advancement of ASO candidates through clinical development is increasing demand for scalable and reliable CDMO services. Rising molecular complexity is also prompting pharmaceutical and biotechnology companies to outsource manufacturing to specialized providers. These factors are expected to strengthen demand for oligonucleotide CDMO services supporting ASO development over the forecast period.

"Therapeutic applications segment to grow fastest"

The therapeutic applications segment is projected to grow at the highest CAGR in the oligonucleotide CDMO market, driven by expanding development of oligonucleotide-based therapeutics and increased outsourcing of manufacturing. Therapeutic programs require specialized services for synthesis, purification, analytical testing, and GMP manufacturing. The advancement of ASO, siRNA, and other oligonucleotide candidates through clinical development is increasing demand for scalable, regulatory-compliant manufacturing. Rising molecular complexity is further encouraging pharmaceutical and biotechnology companies to rely on specialized CDMOs. These factors are expected to strengthen demand for CDMO services supporting therapeutic applications during the forecast period.

"US is expected to grow at the highest CAGR during the forecast period"

The US is expected to post the highest CAGR in the oligonucleotide CDMO market, driven by a strong concentration of pharmaceutical and biotechnology companies with active oligonucleotide development pipelines. Established CDMO infrastructure and specialized capabilities in oligonucleotide synthesis, purification, analytical testing, and GMP manufacturing further support market growth. Rising demand for clinical and commercial manufacturing capacity is also strengthening outsourcing activity. Advancements in ASO, siRNA, and other oligonucleotide programs are driving demand for scalable manufacturing and specialized process development. These factors are expected to support continued expansion of the US oligonucleotide CDMO market over the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side - 70% and Demand Side- 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe - 25%, Asia Pacific - 25%, Latin America - 5%, the Middle East & Africa - 5%

Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), Maravai LifeSciences (US), Lonza (Switzerland), Eurofins Scientific (Luxembourg), Danaher Corporation (US), GenScript (US), Syngene International Limited (India), Ajinomoto Co., Inc. (Japan), EUROAPI (France), ST Pharm (South Korea), Kaneka Corporation (Japan), PolyPeptide Group (Switzerland), Aurigene Pharmaceutical Services Ltd. (India), BioSpring (Germany), Nippon Shokubai Co., Ltd. (Japan), LGC Biosearch Technologies (UK), Oligo Factory (US), Corden Pharma (Switzerland), Bio-Synthesis, Inc. (US), Microsynth (Switzerland), Synoligo Biotechnologies, Inc. (US), Hongene Biotech Corporation (China), Sylentis, S.A. (Spain), Creative Biogene (US), Nitto Avecia (US), and NJ Bio, Inc. (US) are key companies providing oligonucleotide CDMO services.

Research Coverage

This research report categorizes the oligonucleotide CDMO market by service type (contract manufacturing {commercial stage, clinical stage}, contract development, and other services {analytical testing, analytical method development & validation, and standalone fill-finish services}), by type (antisense oligonucleotides, small interfering RNA, and other oligonucleotides), by application (therapeutic applications, research applications, and diagnostic applications), by end user (pharmaceutical & biotechnology companies, diagnostic companies, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report's scope encompasses detailed information on the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide CDMO market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overviews, service portfolios, key strategies, service expansions, acquisitions, and recent developments related to the oligonucleotide CDMO market. This report also includes a competitive analysis of emerging startups in the oligonucleotide CDMO industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and provide information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Growing demand for pre-clinical-to-commercial oligo CDMOs, Increase in CDMO partnerships for scalability, Increasing focus on precision/personalized medicine), restraints (Complexities associated with therapeutic oligonucleotide manufacturing), opportunities (Increasing use of oligos in CRISPR-Cas9 applications, Growing demand for complex and modified oligonucleotides), and challenges (Lack of sustainable supply chain, Limited scalability of GMP oligonucleotide synthesis) influencing the market growth
• Service Development/Innovation: Detailed insights into newly launched services and innovations in the oligonucleotide CDMO market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and services of leading players, Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), WuXi AppTec (China), and ST Pharm (South Korea), among others, for the oligonucleotide CDMO market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDES CDMO MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
• 3.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY TYPE
• 3.3 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY SERVICE TYPE, 2026 VS. 2031

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing demand for Pre-Clinical-to-Commercial oligo CDMOs
    • 4.2.1.2 Increase in CDMO partnerships for scalability
    • 4.2.1.3 Increasing focus on precision/personalized medicine
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
    • 4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Lack of sustainable supply chain
    • 4.2.4.2 Limited scalability of GMP oligonucleotide synthesis
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
  • 5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
• 5.5 KEY CONFERENCES & EVENTS, 2026-2027
• 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.7 INVESTMENT & FUNDING SCENARIO
• 5.8 IMPACT OF 2025 US TARIFF ON OLIGONUCLEOTIDE CDMO MARKET
  • 5.8.1 INTRODUCTION
  • 5.8.2 KEY TARIFF RATES
  • 5.8.3 PRICE IMPACT ANALYSIS
  • 5.8.4 IMPACT ON COUNTRY/REGION
    • 5.8.4.1 US
    • 5.8.4.2 Europe
    • 5.8.4.3 Asia Pacific
  • 5.8.5 IMPACT ON END-USE INDUSTRIES
    • 5.8.5.1 Pharmaceutical & Biotechnology Companies
    • 5.8.5.2 Diagnostic companies
    • 5.8.5.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Process technologies
      • 6.1.1.1.1 Solid-phase synthesis
      • 6.1.1.1.2 Liquid-phase synthesis
      • 6.1.1.1.3 Enzymatic phase synthesis
    • 6.1.1.2 Purification, analysis, and quality control technologies
      • 6.1.1.2.1 Affinity chromatography
      • 6.1.1.2.2 Tangential flow filtration (tff) & ultrafiltration
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Polymerase chain reaction (PCR)
    • 6.1.2.2 Next-generation sequencing (NGS)
    • 6.1.2.3 Microarray technology/hybridization-based assays
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Galnac conjugation/Antibody-oligonucleotide conjugation
    • 6.1.3.2 Lipid nanoparticle (LNP) encapsulation
• 6.2 TECHNOLOGY ROADMAP
• 6.3 FUTURE APPLICATIONS
• 6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET
  • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.4.2 BEST PRACTICES IN AI-ENABLED OLIGONUCLEOTIDE CDMO WORKFLOWS
  • 6.4.3 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE CDMO MARKET
  • 6.4.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.4.5 CLIENTS' READINESS TO ADOPT AI-INTEGRATED OLIGONUCLEOTIDE CDMO TECHNOLOGIES

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE

• 9.1 INTRODUCTION
• 9.2 CONTRACT MANUFACTURING
  • 9.2.1 COMMERCIAL STAGE
    • 9.2.1.1 Advancing oligonucleotide therapies and demand for reliable commercial-scale GMP supply are driving growth in commercial-stage services
  • 9.2.2 CLINICAL STAGE
    • 9.2.2.1 Advancing clinical pipelines and demand for specialized scalable manufacturing are driving growth in clinical-stage services
• 9.3 CONTRACT DEVELOPMENT
  • 9.3.1 INCREASINGLY COMPLEX OLIGONUCLEOTIDE PIPELINES AND DEMAND FOR OPTIMIZED CLINICAL MANUFACTURING PROCESSES ARE DRIVING CONTRACT DEVELOPMENT GROWTH
• 9.4 OTHER SERVICES
  • 9.4.1 INCREASING MOLECULAR COMPLEXITY AND DEMAND FOR INTEGRATED ANALYTICAL AND DRUG-PRODUCT SUPPORT ARE DRIVING GROWTH IN OTHER SERVICES

10 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 THERAPEUTIC APPLICATIONS
  • 10.2.1 EXPANDING THERAPEUTIC APPLICATIONS AND ADVANCING OLIGONUCLEOTIDE PIPELINES ARE DRIVING DEMAND FOR SPECIALIZED CDMO SERVICES.
• 10.3 RESEARCH APPLICATIONS
  • 10.3.1 EXPANDING GENOMICS, SEQUENCING, CRISPR RESEARCH, AND OUTSOURCED CUSTOM SYNTHESIS DRIVE GROWTH
• 10.4 DIAGNOSTIC APPLICATIONS
  • 10.4.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION ONCOLOGY DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE MANUFACTURING

11 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 ANTISENSE OLIGONUCLEOTIDE (ASO)
  • 11.2.1 ADVANCING ASO PIPELINES AND INCREASING DEMAND FOR SCALABLE GMP MANUFACTURING ARE DRIVING GROWTH
• 11.3 SMALL INTERFERING RNA (SIRNA)
  • 11.3.1 EXPANDING SIRNA PIPELINES AND INCREASING DEMAND FOR SPECIALIZED GMP MANUFACTURING ARE DRIVING GROWTH IN THE MARKET.
• 11.4 OTHER OLIGONUCLEOTIDES
  • 11.4.1 EXPANDING CRISPR AND TARGETED APTAMER APPLICATIONS DRIVE DEMAND FOR SPECIALIZED OLIGONUCLEOTIDE CDMO CAPABILITIES

12 OLIGONUCLEOTIDE CDMO MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 12.2.1 EXPANDING NUCLEIC ACID PIPELINES AND INCREASING OUTSOURCING DRIVE PHARMACEUTICAL AND BIOTECHNOLOGY DEMAND FOR CDMO SERVICES
• 12.3 DIAGNOSTIC COMPANIES
  • 12.3.1 RISING MOLECULAR TESTING AND DEMAND FOR COMPLIANT CUSTOM OLIGOS DRIVE DIAGNOSTIC OUTSOURCING
• 12.4 OTHER END USERS

13 OLIGONUCLEOTIDE CDMO MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 Expanding domestic GMP capacity and increasing outsourcing are driving US oligonucleotide CDMO growth.
  • 13.2.2 CANADA
    • 13.2.2.1 Integrated North American manufacturing networks and growing outsourcing demand are supporting Canada's oligonucleotide CDMO market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Expanding GMP capacity and integrated oligonucleotide partnerships are driving Germany's market growth
  • 13.3.2 UK
    • 13.3.2.1 Strengthening domestic nucleic-acid infrastructure and growing outsourcing demand are driving UK oligonucleotide CDMO growth
  • 13.3.3 FRANCE
    • 13.3.3.1 Strengthening nucleic-acid capabilities and growing outsourcing demand are driving France's oligonucleotide CDMO market
  • 13.3.4 ITALY
    • 13.3.4.1 Specialized oligonucleotide infrastructure and growing demand for integrated development services are supporting Italy's market growth
  • 13.3.5 SPAIN
    • 13.3.5.1 Expanding domestic manufacturing infrastructure and institutional support for therapeutic oligonucleotides are driving Spain's market growth
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Expanding integrated manufacturing capacity and strengthening domestic oligonucleotide supply chains are driving China's market growth
  • 13.4.2 JAPAN
    • 13.4.2.1 Advanced manufacturing capabilities and rising demand for complex oligonucleotide therapeutics are driving Japan's market growth
  • 13.4.3 INDIA
    • 13.4.3.1 Expanding GMP infrastructure and global outsourcing are driving India's oligonucleotide CDMO market
  • 13.4.4 AUSTRALIA
    • 13.4.4.1 Expanding domestic manufacturing and growing biopharmaceutical outsourcing are supporting Australia's oligonucleotide CDMO market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Synthetic biology, organoid-based screening, and AI-enabled discovery to support market growth
  • 13.4.6 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Infectious-disease research, shared protein-production infrastructure, and vaccine innovation to drive market
  • 13.5.2 MEXICO
    • 13.5.2.1 Nearshoring and expanding regional manufacturing capabilities are supporting Mexico's oligonucleotide CDMO market
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 GCC
    • 13.6.1.1 Saudi Arabia
      • 13.6.1.1.1 Biotechnology localization and expanding genomic medicine capabilities are driving Saudi Arabia's oligonucleotide CDMO market
    • 13.6.1.2 UAE
      • 13.6.1.2.1 Growing biopharmaceutical activity and need for localized advanced-therapy manufacturing are creating opportunities for UAE's oligonucleotide CDMO services
    • 13.6.1.3 Rest of GCC Countries
  • 13.6.2 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 GROWING GENOMICS ACTIVITY AND LIMITED LOCAL MANUFACTURING CAPACITY ARE CREATING OPPORTUNITIES FOR OLIGONUCLEOTIDE CDMO SERVICES ACROSS AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE CDMO MARKET, 2023-2026
• 14.3 REVENUE ANALYSIS
• 14.4 MARKET SHARE ANALYSIS
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE CDMO MARKET), 2025
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
• 14.7 COMPETITIVE SCENARIO
  • 14.7.1 PRODUCT APPROVALS
• 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 14.9 COMPANY VALUATION AND FINANCIAL METRICS
  • 14.9.1 COMPANY VALUATION AND FINANCIAL METRICS FOR OLIGONUCLEOTIDE CDMO PLAYERS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 BACHEM INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product/Service launches
      • 15.1.1.3.2 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 THERMO FISHER SCIENTIFIC INC.
    • 15.1.2.1 Business overview
    • 15.1.2.2 Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product/Service launches
      • 15.1.2.3.2 Expansions
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 AGILENT TECHNOLOGIES, INC.
    • 15.1.3.1 Business overview
    • 15.1.3.2 Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product/Service launches
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 WUXI APPTEC
    • 15.1.4.1 Business overview
    • 15.1.4.2 Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths/Right to win
      • 15.1.4.4.2 Strategic choices made
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 MARAVAI LIFESCIENCES
    • 15.1.5.1 Business overview
    • 15.1.5.2 Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Deals
  • 15.1.6 LONZA
    • 15.1.6.1 Business overview
    • 15.1.6.2 Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Deals
      • 15.1.6.3.2 Expansions
  • 15.1.7 EUROFINS SCIENTIFIC
    • 15.1.7.1 Business overview
    • 15.1.7.2 Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Expansions
  • 15.1.8 DANAHER CORPORATION
    • 15.1.8.1 Business overview
    • 15.1.8.2 Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Expansions
      • 15.1.8.3.2 Other Developments
  • 15.1.9 GENSCRIPT
    • 15.1.9.1 Business overview
    • 15.1.9.2 Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Expansions
  • 15.1.10 SYNGENE INTERNATIONAL LIMITED
    • 15.1.10.1 Business overview
    • 15.1.10.2 Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product/Service launches
      • 15.1.10.3.2 Expansions
  • 15.1.11 EUROAPI
    • 15.1.11.1 Business overview
    • 15.1.11.2 Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Deals
      • 15.1.11.3.2 Expansions
  • 15.1.12 AJINOMOTO CO., INC.
    • 15.1.12.1 Business overview
    • 15.1.12.2 Services offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Expansions
      • 15.1.12.3.2 Deals
  • 15.1.13 ST PHARM
    • 15.1.13.1 Business overview
    • 15.1.13.2 Services offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Expansions
      • 15.1.13.3.2 Deals
    • 15.1.13.4 MnM view
      • 15.1.13.4.1 Key strengths
      • 15.1.13.4.2 Strategic choices
      • 15.1.13.4.3 Weaknesses and competitive threats
  • 15.1.14 KANEKA CORPORATION
    • 15.1.14.1 Business overview
    • 15.1.14.2 Services offered
  • 15.1.15 POLYPEPTIDE GROUP
    • 15.1.15.1 Business overview
    • 15.1.15.2 Services offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Expansions
  • 15.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
    • 15.1.16.1 Business overview
    • 15.1.16.2 Services offered
  • 15.1.17 BIOSPRING
    • 15.1.17.1 Business overview
    • 15.1.17.2 Services offered
    • 15.1.17.3 Recent developments
      • 15.1.17.3.1 Service approvals
      • 15.1.17.3.2 Expansions
  • 15.1.18 NIPPON SHOKUBAI CO., LTD.
    • 15.1.18.1 Business overview
    • 15.1.18.2 Services offered
    • 15.1.18.3 Recent developments
      • 15.1.18.3.1 Service launch
      • 15.1.18.3.2 Expansions
  • 15.1.19 LGC BIOSEARCH TECHNOLOGIES
    • 15.1.19.1 Business overview
    • 15.1.19.2 Services offered
    • 15.1.19.3 Recent developments
      • 15.1.19.3.1 Service launch
      • 15.1.19.3.2 Deals
      • 15.1.19.3.3 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 OLIGO FACTORY
  • 15.2.2 CORDEN PHARMA
  • 15.2.3 BIO-SYNTHESIS, INC.
  • 15.2.4 MICROSYNTH
  • 15.2.5 SYNOLIGO BIOTECHNOLOGIES, INC.
  • 15.2.6 HONGENE BIOTECH CORPORATION
  • 15.2.7 SYLENTIS, S.A.
  • 15.2.8 CREATIVE BIOGENE
  • 15.2.9 NITTO AVECIA
  • 15.2.10 NJ BIO, INC.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Key data from primary sources
    • 16.1.2.2 Key primary participants
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Key industry insights
• 16.2 MARKET SIZE ESTIMATION
  • 16.2.1 GLOBAL OLIGONUCLEOTIDE CDMO MARKET ESTIMATION, 2025
  • 16.2.2 SEGMENTAL MARKET SIZE ESTIMATION
• 16.3 MARKET GROWTH RATE PROJECTIONS
• 16.4 DATA TRIANGULATION
• 16.5 FACTOR ANALYSIS
• 16.6 RESEARCH ASSUMPTIONS
• 16.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS